The Medicines and Healthcare products Regulatory Agency (MHRA) announced on 14 August 2026 that it had approved vimseltinib, marketed as Romvimza, for adult patients with tenosynovial giant cell tumour (TGCT) when the condition impacts movement or where surgery is not an option. The marketing authorisation was granted to Deciphera Pharmaceuticals that day through the International Recognition Procedure Route B.

TGCT is a rare non-cancerous tumour that forms around a joint and tendons, usually in a single joint and most often the knee or ankle of young and middle-aged adults. Symptoms can include pain, swelling, stiffness and difficulty moving. According to the MHRA, vimseltinib works by blocking proteins that drive tumour growth and is taken as a capsule twice a week. The agency said the medicine is subject to additional monitoring and should not be used in pregnancy.

The MHRA listed common side effects, which may affect more than 1 in 5 people, including tiredness, swelling around the eyes, ankles and feet, itching, rashes, high blood pressure, increased liver enzymes, cholesterol and creatinine levels, and decreased neutrophils. Julian Beach, MHRA Executive Director, Healthcare Quality and Access, said the approval offers a new option for patients with symptoms who are unsuitable for surgery, and that the agency would keep safety under close review. The MHRA said product information would be published on its website within 7 days of approval.